This content is machine translated Polymyalgia rheumatica and giant cell arteritis New consensus paper recommends “treat-to-target” strategy Giant cell arteritis and polymyalgia rheumatica are inflammatory rheumatic diseases that often occur together and almost exclusively affect people over the age of 50. Glucocorticoids are initially used for both…
View Post 5 min This content is machine translated Systemic lupus erythematosus DORIS and LLDAS are also worthwhile for severe cases DORIS (Definition of Remission in SLE) and LLDAS (Lupus Low Disease Activity State) are established measures of remission in systemic lupus erythematosus (SLE), but their feasibility and validity have not…
View Post 4 min This content is machine translated Casuistry SLE with kidney damage does not always have to be lupus nephritis The distinction between IgA nephropathy and lupus nephritis in patients with systemic lupus erythematosus (SLE) has important prognostic and therapeutic implications. Physicians from China describe a case of systemic lupus…
View Post 5 min This content is machine translated Rheumatoid arthritis JAK inhibitor reduces pain for a long time Patients with active rheumatoid arthritis often suffer from considerable pain. Therefore, pain control is an important treatment goal in this patient group. In a post-hoc analysis of the FINCH studies…
View Post 4 min This content is machine translated SLE: Early use of biologics? Findings from the “Leeds SLE Inception Cohort” If systemic lupus erythematosus (SLE) cannot be adequately controlled with hydroxychloroquine and cortisone preparations, the use of immunomodulatory or immunosuppressive agents and/or biologics should be considered according to current EULAR…
View Post 8 min This content is machine translated Rheumatoid arthritis News on gender medicine in the RA Rheumatoid arthritis (RA) is the most common inflammatory rheumatic joint disease, affecting women 2-3 times more often than men. The exact interaction of immunological, hormonal and genetic factors has not… CME-Test
View Post 7 min This content is machine translated Interview with Prof. Thomas Kündig (USZ) and Prof. Diego Kyburz (USB) “You have to stop treating psoriasis as just a skin disease”. In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that…
View Post 7 min This content is machine translated Sponsored Content: Extra-musculoskeletal manifestations in rheumatic diseases Rheumatic diseases and their connection to the gut Patients with spondyloarthropathies (SpA) often suffer from extra-musculoskeletal manifestations (EMMs), which can also affect the gut [1, 2]. These multifaceted diseases with a complex clinical picture have both physiological and…
View Post 4 min This content is machine translated TYK2 inhibition in psoriasis What’s new? The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 andtyrosine kinase-2 (TYK2).Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with…
View Post 4 min This content is machine translated IL-23-i for psoriasis Real-world studies with a focus on PROs Individual therapy goals are playing an increasingly important role in the modern, guideline-oriented treatment of psoriasis. In this context, real-world studies with biologics often not only record the reduction in…
View Post 5 min This content is machine translated Rare diseases Muckle-Wells syndrome This rare autoinflammatory syndrome, caused by a genetic mutation, was first described in 1962 by the English doctors Thomas James Muckle and Michael Vernon Wells. Muckle-Wells syndrome is one of…
